465 related articles for article (PubMed ID: 29192692)
1. Detecting the earliest radiological signs of bisphosphonate-related osteonecrosis.
Devlin H; Greenwall-Cohen J; Benton J; Goodwin TL; Littlewood A; Horner K
Br Dent J; 2018 Jan; 224(1):26-31. PubMed ID: 29192692
[TBL] [Abstract][Full Text] [Related]
2. Medication-related osteonecrosis of the jaw: Prevention, diagnosis and management in patients with cancer and bone metastases.
Otto S; Pautke C; Van den Wyngaert T; Niepel D; Schiødt M
Cancer Treat Rev; 2018 Sep; 69():177-187. PubMed ID: 30055439
[TBL] [Abstract][Full Text] [Related]
3. [Position paper on medication-related osteonecrosis of the jaw (MRONJ)].
Svejda B; Muschitz Ch; Gruber R; Brandtner Ch; Svejda Ch; Gasser RW; Santler G; Dimai HP
Wien Med Wochenschr; 2016 Feb; 166(1-2):68-74. PubMed ID: 26847441
[TBL] [Abstract][Full Text] [Related]
4. What is the effect of anti-resorptive drugs (ARDs) on the development of medication-related osteonecrosis of the jaw (MRONJ) in osteoporosis patients: A systematic review.
Aljohani S; Fliefel R; Ihbe J; Kühnisch J; Ehrenfeld M; Otto S
J Craniomaxillofac Surg; 2017 Sep; 45(9):1493-1502. PubMed ID: 28687467
[TBL] [Abstract][Full Text] [Related]
5. Quantitative Segmentation Analysis of the Radiological Changes by Using ITK-SNAP: Risk Assessment of the Severity and Recurrence of Medication-related Osteonecrosis of the Jaw.
Zhou YQ; Son GH; Shi YQ; Yu YJ; Li MY; Zhang Q; Zou DH; Zhang ZY; Yang C; Wang SY
Int J Med Sci; 2021; 18(10):2209-2216. PubMed ID: 33859529
[No Abstract] [Full Text] [Related]
6. [Bisphosphonate-related osteonecrosis of the jaw].
Atanes-Bonome P; Atanes-Bonome A; Ríos-Lage P; Atanes-Sandoval AD
Semergen; 2014 Apr; 40(3):143-8. PubMed ID: 24001573
[TBL] [Abstract][Full Text] [Related]
7. Bisphosphonate-related osteonecrosis of the jaw: from the sine qua non condition of bone exposure to a non-exposed BRONJ entity.
Koth VS; Figueiredo MA; Salum FG; Cherubini K
Dentomaxillofac Radiol; 2016; 45(7):20160049. PubMed ID: 27167455
[TBL] [Abstract][Full Text] [Related]
8. The Prevention of Medication-related Osteonecrosis of the Jaw.
Poxleitner P; Engelhardt M; Schmelzeisen R; Voss P
Dtsch Arztebl Int; 2017 Feb; 114(5):63-69. PubMed ID: 28241916
[TBL] [Abstract][Full Text] [Related]
9. Medication-related osteonecrosis of the jaw: knowledge and perceptions of medical professionals on the usage of bone modifying agents and dental referrals.
Acharya S; Patil V; Ravindranath V; Kudva A; Nikhil K
J Med Life; 2022 Mar; 15(3):368-373. PubMed ID: 35449990
[TBL] [Abstract][Full Text] [Related]
10. Denosumab-related osteonecrosis of the jaw: a report of 2 cases and review of the literature.
Chehal H; Nikitakis NG; Islam MN; Goodchild JH; Mordini L; Bhattacharyya I
Gen Dent; 2019; 67(1):42-46. PubMed ID: 30644830
[TBL] [Abstract][Full Text] [Related]
11. MRONJ risk of adjuvant bisphosphonates in early stage breast cancer.
Patel V; Mansi J; Ghosh S; Kwok J; Burke M; Reilly D; Nizarali N; Sproat C; Chia K
Br Dent J; 2018 Jan; 224(2):74-79. PubMed ID: 29242516
[TBL] [Abstract][Full Text] [Related]
12. Medication-related osteonecrosis of the jaw: definition and best practice for prevention, diagnosis, and treatment.
Nicolatou-Galitis O; Schiødt M; Mendes RA; Ripamonti C; Hope S; Drudge-Coates L; Niepel D; Van den Wyngaert T
Oral Surg Oral Med Oral Pathol Oral Radiol; 2019 Feb; 127(2):117-135. PubMed ID: 30393090
[TBL] [Abstract][Full Text] [Related]
13. Clinical considerations for medication-related osteonecrosis of the jaw: a comprehensive literature review.
Kawahara M; Kuroshima S; Sawase T
Int J Implant Dent; 2021 May; 7(1):47. PubMed ID: 33987769
[TBL] [Abstract][Full Text] [Related]
14. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics.
Pazianas M; Miller P; Blumentals WA; Bernal M; Kothawala P
Clin Ther; 2007 Aug; 29(8):1548-58. PubMed ID: 17919538
[TBL] [Abstract][Full Text] [Related]
15. Medication-related osteonecrosis of the jaw associated with bisphosphonates and denosumab in osteoporosis.
Bagan J; Peydró A; Calvo J; Leopoldo M; Jiménez Y; Bagan L
Oral Dis; 2016 May; 22(4):324-9. PubMed ID: 26818808
[TBL] [Abstract][Full Text] [Related]
16. The Frequency of Medication-related Osteonecrosis of the Jaw and its Associated Risk Factors.
Dodson TB
Oral Maxillofac Surg Clin North Am; 2015 Nov; 27(4):509-16. PubMed ID: 26362367
[TBL] [Abstract][Full Text] [Related]
17. Medication-related osteonecrosis of the jaw: risk factors in patients under biphosphonate versus patients under antiresorptive-antiangiogenic drugs.
Ghidini G; Manfredi M; Giovannacci I; Mergoni G; Sarraj A; Mureddu M; Giunta G; Bonanini M; Meleti M; Vescovi P
Minerva Stomatol; 2017 Aug; 66(4):135-140. PubMed ID: 28497661
[TBL] [Abstract][Full Text] [Related]
18. Medication-Related Osteonecrosis of the Jaw Around Dental Implants: Implant Surgery-Triggered or Implant Presence-Triggered Osteonecrosis?
Giovannacci I; Meleti M; Manfredi M; Mortellaro C; Greco Lucchina A; Bonanini M; Vescovi P
J Craniofac Surg; 2016 May; 27(3):697-701. PubMed ID: 27092912
[TBL] [Abstract][Full Text] [Related]
19. [Management of medication-related osteonecrosis of the jaw-a review of recent study results in comparison to established strategies].
Tröltzsch M; Tröltzsch M; Pautke C; Otto S
HNO; 2022 Jul; 70(7):499-507. PubMed ID: 35050392
[TBL] [Abstract][Full Text] [Related]
20. Concept, diagnosis and classification of bisphosphonate-associated osteonecrosis of the jaws. A review of the literature.
Gavaldá C; Bagán JV
Med Oral Patol Oral Cir Bucal; 2016 May; 21(3):e260-70. PubMed ID: 26827066
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
